Cellectar Biosciences, Inc.
CLRB
$3.69
$0.071.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.85M | -29.07M | -24.54M | -44.58M | -50.11M |
| Total Depreciation and Amortization | 232.80K | 249.10K | 259.50K | 291.70K | 293.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.27M | -4.35M | -16.08M | -1.57M | 3.63M |
| Change in Net Operating Assets | -3.80M | -1.40M | -3.24M | -1.73M | -78.90K |
| Cash from Operations | -29.69M | -34.58M | -43.60M | -47.58M | -46.27M |
| Capital Expenditure | -61.30K | -61.30K | -82.60K | -104.20K | -309.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -61.30K | -61.30K | -82.60K | -104.20K | -309.70K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.04M | 19.81M | 17.56M | 61.41M | 84.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -22.15M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 8.04M | 19.81M | 17.56M | 61.41M | 61.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -21.71M | -14.83M | -26.13M | 13.72M | 15.28M |